Literature DB >> 6847146

Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy.

W H Theodore, R J Porter.   

Abstract

Sedative-hypnotic antiepileptic drugs have potentially toxic effects, but their removal is often thought to be difficult and dangerous. We completely withdrew all barbiturates and benzodiazepines from 78 patients with intractable epilepsy (48 inpatients and 30 outpatients). Initially, 19 patients had plasma levels of sedative drugs above the therapeutic range; 28 were taking more than one of these drugs. Dosages of nonsedative antiepileptic drugs were adjusted to provide optimal seizure control. After 6 months of outpatient follow-up, 69 patients remained on a nonsedative regimen: 35 (51%) showed improvement in both drug toxicity and seizure control, 13 (19%) in toxicity alone, 8 (12%) in seizure control alone; 12 (16%) were unchanged, and 1 was worse. Of 9 patients restarted on sedative antiepileptic drugs by their private physicians, 4 had more toxic symptoms than at discharge, 1 had more frequent seizures, 3 were unchanged, and 1, who had had a temporal lobectomy after drug withdrawal, had less frequent seizures. Sedative drugs are not necessary for optimal seizure control, even in intractable epilepsy, and they may be safely withdrawn.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847146     DOI: 10.1002/ana.410130316

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

1.  Use of antiepileptic drugs in the elderly population.

Authors:  K S Oles; P Gal; J K Penry; W K Tapscott
Journal:  Public Health Rep       Date:  1987 May-Jun       Impact factor: 2.792

Review 2.  Modern treatment strategies for patients with epilepsy: a review.

Authors:  J S Duncan
Journal:  J R Soc Med       Date:  1991-03       Impact factor: 18.000

3.  Sleep disturbances among patients with epilepsy.

Authors:  Anna Staniszewska; Agnieszka Mąka; Urszula Religioni; Dominik Olejniczak
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-10       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.